After a 6-month period consulting with investors on how to improve the attractiveness of Pershing Square’s listed vehicle, the fund is seeking a London listing.
After recording a profit of close to $3billion on the sale of Allergan to Actavis in 2014, Pershing Square subsequently lost all these profits on the collapse of Valeant between the summer of 2015 and early 2016.
Since our November newsletter, when we talked about Louis Moore Bacon’s sea-change in trading opportunities, we have seen major renewed investor interest in the Global Macro strategy.
Bill Ackman has paid a high price for being one of the most high-profile hedge fund managers in the world. He turned from hero to zero in the last 18 months since extraordinary strong returns made room for a period of very poor performance.
“The recent election in the United States has, in our view, launched nothing short of a sea change in the potential opportunity set for trading markets globally” – Louis Moore Bacon
Robert Citrone was the head of global emerging market investments at famed hedge fund Tiger Management, before founding Discovery Capital Management in 1999.
Legends Fund portfolio manager Ruud Smets interviewed Lansdowne Partners chairman Stuart Roden at the Legends4Legends Conference in Amsterdam on September 15th.
Glenview Capital Partners was up 1.6% in September while having some of its most cautious positioning ever over the lifetime of the fund, with a historically low net exposure.